Meghmani Industries Limited Revenue and Competitors
Estimated Revenue & Valuation
- Meghmani Industries Limited's estimated annual revenue is currently $83.6M per year.
- Meghmani Industries Limited's estimated revenue per employee is $140,000
Employee Data
- Meghmani Industries Limited has 597 Employees.
- Meghmani Industries Limited grew their employee count by 19% last year.
Meghmani Industries Limited's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Regional Sales Manager | Reveal Email/Phone |
2 | Sr. Regional Sales Manager Rajasthan | Reveal Email/Phone |
Meghmani Industries Limited Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7.5M | 284 | 4% | N/A | N/A |
#2 | $130.3M | 931 | 4% | N/A | N/A |
#3 | $73.5M | 525 | 3% | N/A | N/A |
#4 | $19M | 136 | 4% | N/A | N/A |
#5 | $19.9M | 142 | 15% | N/A | N/A |
#6 | $13.3M | 95 | 6% | N/A | N/A |
#7 | $1.7M | 346 | 25% | N/A | N/A |
#8 | $7.5M | 869 | 26% | N/A | N/A |
#9 | $34.3M | 245 | 28% | N/A | N/A |
#10 | $18.1M | 129 | 34% | N/A | N/A |
What Is Meghmani Industries Limited?
Enganged in the manufacturing of Agrochemicals like Pendimethalin, Propanil, Pretilachlor, All traiznes, Glyphosate, Hexaconazole, Propiconazole, Tebuconazole, Tricyclazole, Sulfur 80% WDG, Thiophanate methyl. Company sales revenue is more than 40 million USD.
keywords:N/A
N/A
Total Funding
597
Number of Employees
$83.6M
Revenue (est)
19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Meghmani Industries Limited News
2022-04-17 - Best Small-Cap Stocks To Watch Out Tommorow | DSIJ
Mangalore Refinery &...
2022-04-17 - Permethrin Market Size, Scope And Forecast | Leading ...
... Tagros, Meghmani, Crop Life Science Limited, Aestar, Gharda, Guangdong Liwei ... The detailed study of the industry, industrial sector development and...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $92.5M | 597 | N/A | N/A |
#2 | $242.9M | 598 | 2% | N/A |
#3 | $157M | 598 | -8% | N/A |
#4 | $187.6M | 598 | 8% | N/A |
#5 | $134.8M | 599 | 6% | N/A |